MedTrace Logo

MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)

NCT06212466 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 136

Last updated 2025-07-10

No results posted yet for this study

Summary

A prospective, multicenter, observational, single-arm trial to validate CardioFlux MCG's ability to diagnose myocardial ischemia caused by coronary microvascular dysfunction in patients with suspected ischemia and confirmed no obstructive coronary artery disease (suspected INOCA) by using diagnostic measures of coronary flow reserve (CFR) via invasive angiography as a reference standard for diagnosis.

Conditions

  • Ischemic Heart Disease
  • Coronary Microvascular Disease
  • Angina
  • Myocardial Ischemia

Interventions

DEVICE

CardioFlux

The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity.

Sponsors & Collaborators

  • Genetesis Inc.

    lead INDUSTRY

Principal Investigators

  • Zoe E Swann, PhD · Genetesis Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-03
Primary Completion
2025-04-15
Completion
2025-04-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06212466 on ClinicalTrials.gov